- Full text PDF available (1)
- This year (5)
- Last 5 years (9)
- Last 10 years (9)
Journals and Conferences
OBJECTIVE To investigate the question of whether salvage therapy with the programmed cell death protein 1 (PD-1)-blocking antibodies nivolumab or pembrolizumab with or without bevacizumab offers… (More)
PURPOSE Isocitrate dehydrogenase (IDH)-mutant glioma is a distinct glioma molecular subtype for which no effective molecularly directed therapy exists. Low-grade gliomas, which are 80%-90%… (More)
e14044Background: Up to 20% of meningiomas behave aggressively with high recurrence rates and reduced survival. There is a lack of biomarkers predicting the risk of an unfavorable clinical course a...
2026Background: There is a critical need for more specific and less invasive diagnostic and pharmacodynamic biomarkers in glioblastoma (GBM) patients (pts). Previously, we detected TERT promoter ho...
Purpose of reviewMore effective therapies for glioblastoma are urgently needed. Immunotherapeutic strategies appear particularly promising and are therefore intensively studied. This article reviews… (More)
Rimas Lukas, E. Antonio Chiocca, Sylvia Kurz, John Yu, Joseph Landolfi, Ganesh Rao, John A Barrett, Jill Y. Buck, Nathan Demars, Amy Smith, John Miao, John Zhou, Arnold Gelb, Laurence JN Cooper… (More)
Seizures are common in patients with brain tumors and may have a significant impact on quality of life. The actual seizure risk varies based on tumor histology and tumor location. Seizures are most… (More)